PARP1 and neoplasm: Using the same methods for copy number analysis as utilized for the primary/recurrence cohort to analyze the TCGA Level 1 data, we found a high prevalence of PARP1 gains and amplifications in both tumor types, with no differences based on BRCA1/2 status (Supplementary Fig. 6b and Supplementary Data 11).